Background: Asia is a huge and populous continent with diverse economies where the status of renal replacement therapy varies among different countries. Summary: The penetration of dialysis is poor among low income countries like India and China. A lack of trained nephrologists and limited numbers of dialysis facilities plague South Asian countries. Most of the hemodialysis centers are in the private sector; the few centers that are government-run or run by charitable organizations cannot meet growing needs. China has shown that twice-a-week hemodialysis can be feasible in female patients with small build. Peritoneal dialysis (PD) has less penetration among the developing countries than the developed countries in Asia. Novel schemes in India including the ‘once-in-a-lifetime payment' scheme and an insurance scheme for peritonitis are attracting more patients to PD. New biocompatible PD solutions and home care facilities have brought down the peritonitis rates. The PD-first policy in Thailand alongside the domestic manufacture of PD fluids has decreased the cost of PD there. Iran has shown drastic changes in its PD policy (from 0 to 1,150 recruitments in 5 years) in spite of its high transplantation rate. Home hemodialysis is practiced in mostly affluent countries like Japan, where again it accounts for only 0.1% of all hemodialysis. Key Messages: Developing countries should have more budgetary allocation for chronic ailments such as chronic kidney disease that can be utilized for training programs and establishing dialysis units, and thus meet the growing demands for renal replacement therapy. PD should be encouraged and adopted as first modality of renal replacement therapy considering its ease and economy.

Keywords:
Renal replacement therapy, Hemodialysis, Continuous ambulatory peritoneal dialysis, Asian countries
1.
Válek A, Wing AJ: Development of dialysis and transplant activities in the world during the seventies of the 20th century. Z Exp Chir Transplant Kunstliche Organe 1984;17:69-75.
2.
Lai KN, Lo WK: Optimal peritoneal dialysis for patients from Hong Kong. Perit Dial Int 1999;19(suppl 3):S26-S31.
3.
Blake PG: Factors affecting international utilization of peritoneal dialysis: implications for increasing utilization in the United States. Semin Dial 1999;12:365-369.
4.
Hörl WH, de Alvaro F, Williams PF: Healthcare systems and end-stage renal disease (ESRD) therapies: an international review: access to ESRD treatments. Nephrol Dial Transplant 1999;14(suppl 6):10-15.
5.
Chugh KS: Five decades of Indian nephrology: a personal journey. Am J Kidney Dis 2009;54:753-763.
6.
Modi G, Jha V: Incidence of ESRD in India. Kidney Int 2011;79:573.
7.
Modi GK, Jha V: The incidence of end-stage renal disease in India: a population-based study. Kidney Int 2006;70:2131-2133.
8.
JhaV: Current status of end-stage renal disease care in India and Pakistan. Kid Int Suppl 2013;3:157-160.
9.
United Nations Development Program. Human Development Report. 2006. http://hdr.undp.org/hdr2006 (accessed 30 July 2007).
10.
Agarwal SK, Srivastava RK: Chronic kidney disease in India: challenges and solutions. Nephron Clin Pract 2009;111:c197-c203.
11.
Parameswaran S, Geda SB, Rathi M, Kohli HS, Gupta KL, Sakhuja V, Jha V: Referral pattern of end-stage renal disease patients and its impact on outcome at a public sector hospital. Natl Med J India 2011;24:208-213.
12.
Jeloka TK, Upase S, Chitikeshi S: Monthly cost of three sessions a day peritoneal dialysis is same as of thrice a week hemodialysis in self-paying Indian patients. Indian J Nephrol 2012;22:39-41.
13.
Dialysis and Transplantation Registration Group. National Dialysis and Transplant Report. Zhonghua Shenzangbing Zazhi 2001;17:77-78.
14.
Zuo L, Wang M: Current burden and probable increasing incidence of ESRD in China. Clin Nephrol 2010;74:20-22.
15.
Zuo L, Wang M: Current status of hemodialysis treatment in Beijing China. Ethn Dis 2006;16(suppl 2):31-34.
16.
Bieber B, Qian J, Anand S, Yan Y, Chen N, Wang M, Wang M, Zuo L, Hou FF, Pisoni RL, Robinson BM, Ramirez SP: Two-times weekly hemodialysis in China: frequency, associated patient and treatment characteristics and quality of life in the China Dialysis Outcomes and Practice Patterns study. Nephrol Dial Transplant 2013;29:1770-1777.
17.
US Renal Data System, USRDS 2011 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases: Bethesda, MD: 2011.
18.
Dialysis in the Kingdom of Saudi Arabia. Saudi J Kidney Dis Transpl 2013;24:853-61.
19.
Arefzadeh A, Lessanpezeshki M, Seifi S: The cost of hemodialysis in Iran. Saudi J Kidney Dis Transpl 2009;20:307-311.
20.
Grassmann A, Gioberge S, Moeller S, Brown G: ESRD patients in 2004: global overview of patient numbers, treatment modalities and associated trends. Nephrol Dial Transplant 2005;20:2587-2593.
21.
Hidai H: Inequality of renal replacement therapy in the low-income countries. Nephrol Dial Transplant 2007;22:663-665.
22.
Nakai S, Suzuki K, Masakane I, Wada A, Itami N, Ogata S, Kimata N, Shigematsu T, Shinoda T, Syouji T, Taniguchi M, Tsuchida K, Nakamoto H, Nishi S, Nishi H, Hashimoto S, Hasegawa T, Hanafusa N, Hamano T, Fujii N, Marubayashi S, Morita O, Yamagata K, Wakai K, Watanabe Y, Iseki K, Tsubakihara Y: Overview of regular dialysis treatment in Japan (as of 31 December 2008). Therapeutic Apheresis and Dialysis 2010;14:505-540.
23.
Jin DC: Current Status of Dialysis Therapy in Korea. Korean J Intern Med 2011;26:123-131.
24.
Abraham G, Pratap B, Mathew M: PD in developing countries; in Khanna R, Krediet RT (eds): Nolph and Gokal's Textbook of PD: ed 3. Springer-Verlag US, 2009, pp 885-909.
25.
Abraham G, Pratap B, Sankarasubbaiyan S, Govindan P, Nayak KS, Sheriff R, Naqvi SA: Chronic peritoneal dialysis in South Asia: challenges and future. Perit Dial Int 2008;28:13-19.
26.
Yu X, Yang X: Peritoneal dialysis in China: meeting the challenge of chronic kidney failure. Am J Kidney Dis 2015;65:147-151.
27.
Nakamoto H: Present status and future of peritoneal dialysis in Japan. Contrib Nephrol 2015;185:116-123.
28.
Jain AK, Blake P, Cordy P, Garg AX: Global trends in rates of peritoneal dialysis. J Am Soc Nephrol 2012;23:533-544.
29.
Huang CC, Cheng KF, Wu HD: Survival analysis: comparing peritoneal dialysis and hemodialysis in Taiwan. Perit Dial Int 2008;28(suppl 3):S15-S20.
30.
Chang YK, Hsu CC, Hwang SJ, Chen PC, Huang CC, Li TC, Sung FC:A comparative assessment of survival between propensity score-matched patients with peritoneal dialysis and hemodialysis in Taiwan. Medicine (Baltimore) 2012;91:144-151.
31.
Rhee CM, Lertdumrongluk P, Streja E, Park J, Moradi H, Lau WL, Norris KC, Nissenson AR, Amin AN, Kovesdy CP, Kalantar-Zadeh K: Impact of age, race and ethnicity on dialysis patient survival and kidney transplantation disparities. Am J Nephrol 2014;39:183-194.
32.
van den Beukel TO, Jager KJ, Siegert CE, Schoones JW, Dekker FW: Racial minority groups on dialysis in Europe: a literature review. Clin Nephrol 2010;74(suppl 1):S78-S84.
33.
Abboud O: Incidence, prevalence, and treatment of end-stage renal disease in the Middle East. Ethn Dis 2006;16(suppl 2):S2-S4.
34.
Ghods AJ, Savaj S: Iranian model of paid and regulated living-unrelated kidney donation. Clin J Am Soc Nephrol 2006;1:1136-1145.
35.
Mahdavi-Mazdeh M, Zamyadi M, Nafar M: Assessment of management and treatment responses in haemodialysis patients from Tehran province, Iran. Nephrol Dial Transplant 2007;23:288-293.
36.
Mendelssohn DC, Pierratos A: Reformulating the integrated care concept for the new millennium. Perit Dial Int 2002;22:5-8.
37.
Japanese Society of Dialysis Therapy (JSDT): Current Status of Chronic Dialysis Patients in Japan, December 31, 2010. Tokyo, JSDT, 2011.
38.
MacGregor MS, Agar JWM, Blagg CR: Home haemodialysis: international trends and variation. Nephrol Dial Transplant 2006;21:1934-1945.
39.
Lin X, Yan Y, Ni Z, Gu L, Zhu M, Dai H, Zhang W, Qian J: Clinical outcome of twice-weekly hemodialysis patients in Shanghai. Blood Purif 2011;33:66-72.
© 2015 S. Karger AG, Basel
2015
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.